Maria I. Vazquez-Mata

Malaga, AN, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Impact of thrombosis on disease progression, cancer and mortality in patients with essential thrombocythemia and polycythemia vera.

Impact of thrombosis on disease progression, cancer and mortality in patients with essential thrombocythemia and polycythemia vera.

Journal: Blood cancer journal

Published: January 30, 2026

Mutational profile and cardiovascular risk factors impact prognosis in triple-negative essential thrombocythemia.

Mutational profile and cardiovascular risk factors impact prognosis in triple-negative essential thrombocythemia.

Journal: Leukemia

Published: January 23, 2026

Impact of Atrial Fibrillation on the Risk of Thrombosis and Bleeding for Patients With Polycythemia Vera and Essential Thrombocytosis in the Real World.

Impact of Atrial Fibrillation on the Risk of Thrombosis and Bleeding for Patients With Polycythemia Vera and Essential Thrombocytosis in the Real World.

Journal: American journal of hematology

Published: January 19, 2026

Coexisting Myeloproliferative and Lymphoid Neoplasms: A European Multicenter Retrospective Study.

Coexisting Myeloproliferative and Lymphoid Neoplasms: A European Multicenter Retrospective Study.

Journal: American journal of hematology

Published: June 23, 2025

Real world outcomes of momelotinib in myelofibrosis patients with anemia: results from the MOMGEMFIN study.

Real world outcomes of momelotinib in myelofibrosis patients with anemia: results from the MOMGEMFIN study.

Journal: Blood cancer journal

Published: December 15, 2024

Application of IPSET-thrombosis in 1366 Patients Prospectively Followed From the Spanish Registry of Essential Thrombocythemia.

Application of IPSET-thrombosis in 1366 Patients Prospectively Followed From the Spanish Registry of Essential Thrombocythemia.

Journal: HemaSphere

Published: February 06, 2023

Correction to: Low‑risk polycythemia vera treated with phlebotomies: clinical characteristics, hematologic control and complications in 453 patients from the Spanish Registry of Polycythemia Vera.

Correction to: Low‑risk polycythemia vera treated with phlebotomies: clinical characteristics, hematologic control and complications in 453 patients from the Spanish Registry of Polycythemia Vera.

Journal: Annals of hematology

Published: October 20, 2022

Low-risk polycythemia vera treated with phlebotomies: clinical characteristics, hematologic control and complications in 453 patients from the Spanish Registry of Polycythemia Vera.

Low-risk polycythemia vera treated with phlebotomies: clinical characteristics, hematologic control and complications in 453 patients from the Spanish Registry of Polycythemia Vera.

Journal: Annals of hematology

Published: July 03, 2022

Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea.

Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea.

Journal: Cancer

Published: October 29, 2021

Natural history of polycythemia vera and essential thrombocythemia presenting with splanchnic vein thrombosis.

Natural history of polycythemia vera and essential thrombocythemia presenting with splanchnic vein thrombosis.

Journal: Annals of hematology

Published: January 08, 2020

Clinico-biological characteristics of patients with myelofibrosis: an analysis of 1,000 cases from the Spanish Registry of Myelofibrosis.

Clinico-biological characteristics of patients with myelofibrosis: an analysis of 1,000 cases from the Spanish Registry of Myelofibrosis.

Journal: Medicina clinica

Published: August 30, 2019

Do chronic myeloid leukemia patients with late "warning" responses benefit from "watch and wait" or switching therapy to a second generation tyrosine kinase inhibitor?

Do chronic myeloid leukemia patients with late "warning" responses benefit from "watch and wait" or switching therapy to a second generation tyrosine kinase inhibitor?

Journal: American journal of hematology

Published: July 16, 2014

Showing 1-12 of 13

Last Updated: 09/26/2026